Blood Podcast

In this episode, Associate Editor Dr. Philippe Armand discusses the Review Series on mantle cell lymphoma with author Dr. Christine Ryan. Both were authors of "Frontline management of mantle cell lymphoma", and discuss shifts in treatments and new research.Find the full review series in Volume 145 Issue 7 of Blood: "Review series on mantle cell lymphoma: sands shifting in the darkness"

Discover groundbreaking rapid assays that enhance the diagnosis of thrombotic thrombocytopenic purpura, minimizing unnecessary treatments. Learn about a powerful combination therapy using CD38 and PD-1 blockade, showing impressive outcomes in relapsed NK/T-cell lymphoma. Dive into a captivating tale of a ‘zombie enzyme’ in CREBBP-mutant lymphomas, and uncover how a bispecific antibody cleverly restores CD40 signaling to help achieve lymphoma cell death.

Discover the groundbreaking mouse model mimicking human sickle cell SC disease, providing insights into treatment possibilities. Explore the promising results of a quadruplet therapy for multiple myeloma, combining isatuximab and others. Unearth the connection between splicing factor mutations and the clonal dynamics of myelodysplastic syndromes, revealing new potential therapeutic approaches. This week’s discussions dive deep into innovative therapies reshaping hematological disease management.

Discover how AI is revolutionizing transplant risk assessment in myelofibrosis, identifying patients with poor outcomes. Explore a feasibility study on preventing priapism in men with sickle cell anemia, showcasing promising adherence to new therapies. Finally, delve into groundbreaking findings that reveal the absence of T-cell exhaustion in newly diagnosed multiple myeloma, challenging existing beliefs and opening doors for innovative treatment strategies.

Discover how social factors like income and education impact access to critical treatments for acute myeloid leukemia. Dive into groundbreaking advances in ex vivo gene therapy aimed at inherited blood disorders. Learn about the significance of inflammatory biomarkers, particularly the soluble oncostatin M receptor, in predicting patient survival rates. The discussion emphasizes the need for improved support systems and innovative therapies to enhance outcomes for those affected by these conditions.

Dr. Mark Roschewski, a clinical investigator at the National Cancer Institute, Dr. Grzegorz Nowakowski from Mayo Clinic, and Dr. Neha Mehta-Shah, an associate professor at Washington University, discuss aggressive non-Hodgkin lymphoma. They highlight the importance of identifying high-risk patients for tailored treatments. The conversation delves into the unique challenges of lymphomas in immune-privileged sites and innovative therapies like BTK inhibitors. They also touch on new options like Polar-RCHIP and the promise of circulating tumor DNA in clinical trials.

Discover the pivotal role of TET3 in chronic GVHD and its potential as a therapeutic target to combat lung fibrosis. Learn about the promising results of rilzabrutinib, a BTK inhibitor, showing significant platelet responses for those suffering from immune thrombocytopenia. Finally, dive into the complexities of T-cell acute lymphoblastic leukemia and how co-inhibition strategies for pre-TCR and IL-7 pathways may open new avenues for treatment. It's a compelling look into groundbreaking research and innovative approaches in hematology.

Dr. Shaji Kumar, a Mayo Clinic expert and senior author on a pivotal Blood Journal article, discusses groundbreaking findings in multiple myeloma treatment. He reveals that using two simultaneous blood markers for disease progression is 98% accurate, compared to only 82% for sequential methods. This innovative approach could simplify patient assessments, reduce the need for multiple blood draws, and potentially alter international response criteria. Tune in to hear how these changes promise to enhance clinical trials and streamline myeloma management.

Dr. Patrick Foy, a consultative hematologist at the Medical College of Wisconsin, sheds light on the complexities of geriatric hematology. He discusses diagnosing and treating thrombocytopenia in older patients, emphasizing polypharmacy and chronic conditions. The conversation highlights the challenges of anticoagulant management, advocating for careful medication assessments. Additionally, Foy stresses the importance of collaboration among healthcare providers and involving patients in treatment decisions to enhance care for the aging population.

Dive into the fascinating world of leukemia stem cells as researchers use single-cell multi-omics to identify unique subpopulations, paving the way for new treatments. Discover how cyclophosphamide can alleviate non-immune neurotoxicities in CAR T-cell therapy patients, stressing the need for prompt management. Also, explore the intriguing effects of glycosylation on von Willebrand factor half-life, comparing recombinant and plasma-derived options and their impact on future therapies. Science and a glimpse into innovative treatments await!